Aptevo Therapeutics logo

Aptevo TherapeuticsNASDAQ: APVO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 July 2016

Next earnings report:

05 March 2025

Last dividends:

N/A

Next dividends:

N/A
$4.84 M
-94%vs. 3y high
12%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 10 min ago
$0.26-$0.03(-9.83%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

APVO Latest News

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
accesswire.com07 November 2024 Sentiment: POSITIVE

Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress Additional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 8th Raises $5.75 Million in the Quarter SEATTLE, WA / ACCESSWIRE / November 7, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ending September 30, 2024 and provided a business update. Business Highlights Aptevo met multiple clinical milestones in the third quarter, including: Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML).

Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
zacks.com15 August 2024 Sentiment: POSITIVE

Aptevo Therapeutics (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
accesswire.com08 August 2024 Sentiment: POSITIVE

SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of APVO436 in combination with venetoclax and azacitidine for the treatment of Acute Myeloid Leukemia (AML) in frontline patients.

Aptevo Therapeutics Announces Closing of $2.75 Million Offering
accesswire.com01 July 2024 Sentiment: POSITIVE

SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Zacks Investment Research16 April 2024 Sentiment: NEGATIVE

Aptevo's stock drops following the issuance of additional shares at a discounted price, resulting in a significant dilution of existing shareholders.

Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
InvestorPlace11 April 2024 Sentiment: NEGATIVE

Aptevo Therapeutics (NASDAQ: APVO) shares are declining today following the announcement of a public offering in which the company will sell 3.4 million shares of APVO stock at $1.35 per share.

Aptevo to Present at Bio-Europe Conference
Accesswire01 November 2023 Sentiment: POSITIVE

SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company will present at the upcoming Bio-Europe conference occurring November 6-8, 2023 in Munich, Germany. Details of the Company's presentation, which will highlight its pipeline of clinical and pre-clinical bispecific drug candidates designed to fight both solid and hematologic malignancies, are as follows: Date & Time: Tuesday, November 7, 2023 @ 1:15 CET (8:15 Eastern time) Location: Trade Fair Center Messe München, San Sabastian Room, Munich, Germany Presenter: Michelle Nelson, Ph.D.

7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
InvestorPlace30 July 2023 Sentiment: NEGATIVE

Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.

What type of business is Aptevo Therapeutics?

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

What sector is Aptevo Therapeutics in?

Aptevo Therapeutics is in the Healthcare sector

What industry is Aptevo Therapeutics in?

Aptevo Therapeutics is in the Biotechnology industry

What country is Aptevo Therapeutics from?

Aptevo Therapeutics is headquartered in United States

When did Aptevo Therapeutics go public?

Aptevo Therapeutics initial public offering (IPO) was on 20 July 2016

What is Aptevo Therapeutics website?

https://www.aptevotherapeutics.com

Is Aptevo Therapeutics in the S&P 500?

No, Aptevo Therapeutics is not included in the S&P 500 index

Is Aptevo Therapeutics in the NASDAQ 100?

No, Aptevo Therapeutics is not included in the NASDAQ 100 index

Is Aptevo Therapeutics in the Dow Jones?

No, Aptevo Therapeutics is not included in the Dow Jones index

When was Aptevo Therapeutics the previous earnings report?

No data

When does Aptevo Therapeutics earnings report?

The next expected earnings date for Aptevo Therapeutics is 05 March 2025